Abstracts tagged "payers"

Abstract Number: 358 • 2019 ACR/ARP Annual Meeting
Emergency Department Encounters in a Large US Payer Database: Tophaceous versus Non-tophaceous Gout Patients
Meron Mezgebe¹, Megan Francis-Sedlak ¹, Brian LaMoreaux ¹ and Robert Holt ¹, ¹Horizon Therapeutics plc, Lake Forest, IL
Background/Purpose: From 2006 to 2012, gout was the primary indication for ~0.2% of all emergency department visits for adults, as reported in the Nationwide Emergency…
Abstract Number: 1264 • 2018 ACR/ARHP Annual Meeting
Modeling the Costs and Outcomes Associated with Treatment Sequences, with and without Tofacitinib, for Moderately to Severely Active Psoriatic Arthritis in the US
George Bungey¹, Stacey Chang-Douglass¹, Ming-Ann Hsu², Joseph C Cappelleri², Pamela Young³ and John Woolcott³, ¹Decision Resources Group, London, United Kingdom, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Psoriatic Arthritis (PsA) is a chronic progressive inflammatory condition associated with significant direct and indirect costs. Tofacitinib is an oral Janus kinase inhibitor for…
Abstract Number: 2277 • 2014 ACR/ARHP Annual Meeting
Inpatient Pediatric Rheumatic Diseases: Characteristics, Cost and Trends
Monica Mahajan¹, Mohammad Shah², Mary Toth^3,4, Neil McNinch⁵ and Moussa El-Hallak⁶, ¹Department of Pediatrics, Akron Children's Hospital, Akron, OH, ²Patient Safety and Quality Services, Akron Children's Hospital, Akron, OH, ³Akron Children's Hospital, Akron, OH, ⁴Rheumatology, Akron Children's Hospital, Akron, OH, ⁵Rebecca D. Considine Research Institute, Akron Children's Hospital, Akron, OH, ⁶Dept of Pediatric Rheumatology, Akron Children's Hospital, Akron, OH
Background/Purpose: Childhood rheumatic diseases (cRD) have wide spectrum of complexity and disease course from mild disease to acute fulminate disease and even sudden death. Physicians…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].